ICU Medical (NASDAQ:ICUI) Hits New 12-Month High – Here’s What Happened

ICU Medical, Inc. (NASDAQ:ICUI)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $167.00 and last traded at $157.1960, with a volume of 893 shares traded. The stock had previously closed at $157.60.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. KeyCorp dropped their price objective on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a research note on Monday, April 27th. Zacks Research upgraded ICU Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Piper Sandler dropped their price target on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. BTIG Research began coverage on ICU Medical in a report on Monday, June 15th. They issued a “buy” rating and a $170.00 price target for the company. Finally, Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Three research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $168.40.

ICU Medical Stock Up 2.9%

The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The company has a market capitalization of $3.95 billion, a PE ratio of 85.38, a P/E/G ratio of 2.14 and a beta of 0.76. The business’s 50 day simple moving average is $139.36 and its 200 day simple moving average is $139.03.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The business’s revenue was down 12.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, analysts anticipate that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares in the company, valued at $978,363.60. This represents a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Hilton Head Capital Partners LLC purchased a new stake in shares of ICU Medical in the 4th quarter valued at approximately $32,000. Covestor Ltd increased its holdings in ICU Medical by 22.1% in the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 126 shares during the last quarter. Strs Ohio increased its holdings in ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 300 shares during the last quarter. Rockefeller Capital Management L.P. raised its position in ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 146 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new stake in ICU Medical in the fourth quarter valued at approximately $120,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.